Single compound
Bacteriostatic water
Preserved aqueous diluent
CA$10.99
Research pathway
Single compoundMelanotan II
Cyclic α-MSH analogue — melanocortin agonist
CA$105.00
Single compoundMOTS-c
Mitochondrial peptide — AMPK activation · Preclinical
CA$115.00Evidence tierAnimalLee et al., Cell Metabolism 20151 studyThe study reported folate-cycle and AMPK findings alongside mouse metabolic observations. ↗Murine skeletal muscle, myotubes, and mouse diet/age modelsLee et al., Cell Metabolism 2015Animal
Single compoundNAD+
Redox coenzyme — sirtuin and PARP substrate
CA$50.00
Single compoundGHK-Cu
Copper tripeptide — collagen and ECM synthesis · In vitro
CA$35.00
Research pathwayMetabolic research5-Amino-1MQ
NNMT inhibitor — NAD salvage pathway · Preclinical
CA$45.00Evidence tierAnimalNeelakantan et al., Biochemical Pharmacology 20181 studyThe study reported increased NAD+ and SAM in adipocytes and reduced adiposity in diet-induced-obese mice. ↗Differentiated adipocytes and diet-induced-obese miceNeelakantan et al., Biochemical Pharmacology 2018Animal
Research pathwayMetabolic researchRetatrutide
Triple agonist — GIP, GLP-1, glucagon · Phase 3
CA$80.00& upEvidence tierPhase 3Bajaj et al., Lancet 20264 studiesThe trial reported a −24.2% least-squares mean body-weight change in one study arm. ↗338 adults with obesity, or overweight plus a weight-related condition, without diabetesJastreboff et al., NEJM 2023Phase 1–2
Research pathwayMetabolic researchTirzepatide
Dual agonist — GIP, GLP-1 · Phase 3
CA$50.00& upEvidence tierPhase 3Jastreboff et al., NEJM 20222 studiesThe trial reported a −20.9% mean body-weight change in one study arm. ↗2,539 adults with obesity, or overweight plus a complication, excluding diabetesJastreboff et al., NEJM 2022Phase 3
Single compoundBPC-157
Pentadecapeptide — tissue repair models · Preclinical
CA$60.00& up
Single compoundIpamorelin
Selective GHS-R1a agonist — GH release · Preclinical
CA$55.00& up
Single compoundIGF-1 LR3
IGF-1 analogue — reduced IGFBP affinity · In vitro
CA$55.00& up
Single compoundTesamorelin
GHRH analogue — approved indication exists · Phase 3
CA$170.00Evidence tierPhase 3Falutz et al., NEJM 20072 studiesThe trial reported a −15.2% CT visceral-adipose-tissue change compared with +5.0% for placebo. ↗412 HIV-positive adults with abdominal-fat accumulationFalutz et al., NEJM 2007Phase 3
